India Allergy Diagnostics Market – Industry Trends and Forecast to 2029

Market Analysis and Size

According to the WHO (World Health Organization), nearly 80% of the world's population lives in cities, and as a result, air quality has a substantial impact on them, mainly in low-income nations. In addition, multiple studies have linked air pollution to allergic rhinitis, asthma, and other disorders, leading to an increase in allergy diagnoses. Although allergies can affect practically every organ in the body and can be triggered by a variety of external causes, there are a few common themes that should be highlighted in research efforts. Effective prevention, curative therapy, and accurate, early diagnosis, as with many other chronic diseases, are key unmet requirements. In order to organise or re-categorize clinical symptoms into more coherent, consistent, and treatment-responsive groupings, detailed phenotyping/endotyping is widely required.

Data Bridge Market Research analyses that the India allergy diagnostics market which was USD 4.25 billion in 2021, would rocket up to USD 9.72 billion by 2029, and is expected to undergo a CAGR of 10.9% during the forecast period 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Allergies affect nearly every organ in the body in a variety of ways, with a wide range of symptoms, and hence their manifestations span a vast range of phenotypes. According to studies in Europe, up to 30% of the population suffers from allergic rhino conjunctivitis, 20% suffer from asthma, and 15% suffer from allergic skin diseases. Food allergies are growing more common and severe; occupational allergies, medication allergies, and insect sting allergies (which can be lethal) are all contributing to the allergy epidemic.

India Allergy Diagnostics Market Dynamics

Drivers

• Increasing environmental pollution levels

Exposure to indoor and outdoor air pollution, allergies, and occupational exposure are the key risk factors for chronic respiratory illnesses. The prevalence of allergy diseases is higher in city dwellers than in rural people due to the higher exposure to environmental contaminants in cities (as a result of vehicular pollution and industrial activities). More than 80% of people living in cities are exposed to air quality levels that exceed WHO safety recommendations, according to the WHO, while this is a global trend, the implications are particularly severe in low-income countries' urban zones. This is a key indicator of the market's expansion in allergy diagnostics.

• Growing environmental pollution levels

The primary drivers of growth are rising healthcare expenditures and average lifespans, increased understanding of preventative testing, improved diagnostic test offerings, rising lifestyle-related diseases, and government-mandated healthcare treatments.

• Increase in the access to health insurance

The market is dominated by large hospitals and diagnostic laboratories, which can afford high-volume systems due to their large capital budgets. Rising healthcare expenditures aid the expansion of the allergy diagnostics market as a result of high healthcare service costs. In addition, governments in many countries are giving reimbursements and healthcare insurance programs to boost consumer demand for allergy diagnostics around the world.

Opportunities

• Use of m-Health technology in allergy diagnosis

Mobile Health tools for allergic rhinitis (AR) diagnosis published in peer-reviewed papers, the use of mHealth for rhinitis diagnosis is currently limited. A new breed of point-of-care devices has emerged as a result of recent advancements in integrated biosensors, wireless connectivity, and power harvesting techniques. AR, on the other hand, is a highly prevalent disease. Any diagnostic gadget connected to a smartphone (e.g., peak nasal inspiratory flow metres or intranasal biosensors) would have to be affordable.

Restraints/Challenges

• Difficulty in allergy diagnosis

The difficulty in allergy diagnosis is coming up with procedures that are objective, quick, repeatable, cost-effective, sensitive, and specific to the condition. They must be able to recognise exposures and contribute to therapeutic decision-making, preferably in primary care. In addition, tests to monitor therapy response and to compare preclinical and clinical effects across large cohorts and between nations are required.

• Premium costs associated with allergy diagnostic instruments

Market participants update several allergy diagnostic devices, including as luminometers, blot analyzers, scanners, ELISA analyzers, and immunoassay analyzers, on a regular basis. These instruments are more expensive since they have more advanced features and functions (the price of each instrument varies based on its accuracy, flexibility, and TAT). Immunoassay analyzers, for example, cost between USD 10,000 and USD 20,000, while luminometers cost between USD 3,000 and USD 14,000. ELISA readers that are semi-automated cost between USD 2,000 and USD 5,000, while fully automated analyzers cost over USD 14,000. In addition, operating this equipment necessitates extra costs such as maintenance and insurance, laboratory supervision, and overheads (such as utilities, space, and administration).

This India allergy diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the India allergy diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on India Allergy Diagnostics Market

COVID 19 has been the subject of several research to see how it affects allergy diagnostic testing services. According to a survey done in Turkey, allergists prefer to employ telemedicine for asthma and rhinitis during the COVID-19 outbreak at a high rate. However, face-to-face interviews were preferable for more severe allergic illnesses like anaphylaxis and hereditary angioedema. Other countries, such as Italy and the United States, have seen a similar trend. In Australia, face-to-face consultations in outpatient clinics were confined to urgent patients with rheumatological disorders, and roughly 80% of outpatient visits were switched to telemedicine. This also hampered the market's expansion by limiting the restriction and decrease of various diagnostic and treatment services.

Recent Development

• In 2021, Hitachi Chemical Diagnostics, Inc. has been replaced by Minaris Medical America, Inc. By uniting the medical business group firms under the Minaris Medical brand, Hitachi wants to boost its global position and increase commercial activities in the field of in-vitro diagnostics. Showa Denko Materials Co., Ltd own both companies.
• In 2021, PerkinElmer Inc. has reached an agreement to purchase Immunodiagnostic Systems Holdings PLC. PerkinElmer Inc. will be able to strengthen its position in the ImmunoDiagnostics (IDS) industry as a result of the acquisition. EUROIMMUN Medizinische LABORDIAGNOSTIKA AG, a firm that sells allergy products and services, will take over IDS.

India Allergy Diagnostics Market Scope

The India allergy diagnostics market is segmented on the basis of product, allergan, test, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Products

• Assay Kits
• Consumables
• Instruments
• Immunoassay Analyzers
• ELISA Analyzers
• Luminometers
• Other Instruments
• Services

Allergen

• Inhaled Allergens
• Food Allergens
• Drug Allergens
• Other Allergens

Test

• In Vivo Tests
• Skin Prick Tests
• Patch Tests
• Other In Vivo Tests
• In Vitro Tests

End User

• Diagnostic Laboratories
• Hospital-based Laboratories
• Academic Research Institutes
• Other End Users

Distribution Channel

•  Direct
•  Indirect

India Allergy Diagnostics Market Regional Analysis/Insights

The India allergy diagnostics market is analysed and market size insights and trends are provided by country, product, allergan, test, end-user and distribution channel as referenced above.

The countries covered in the India allergy diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the allergy diagnostics market due to rise in the incidence of respiratory allergic disorders. Furthermore, rising awareness of allergy diagnostics and the implementation of in vitro blood tests will propel the allergy diagnostics market in the area to new heights throughout the forecast period.

Asia-Pacific is expected to observe a substantial amount of growth in the allergy diagnostics market due to the rapid change in the improving of healthcare infrastructure. Furthermore, the region's allergy diagnostics market is expected to develop in the next years due to unmet clinical demands and an increasing need for minimally invasive diagnostic tools.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The India allergy diagnostics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for India allergy diagnostics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the India allergy diagnostics market. The data is available for historic period 2010-2020.

Competitive Landscape and India Allergy Diagnostics Market Share Analysis

The India allergy diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to India allergy diagnostics market.

Some of the major players operating in the India allergy diagnostics market are:

• Thermo Fisher Scientific Inc., (US)
• Siemens Healthcare GmbH (Germany)
• Danaher (US)
• Omega Diagnostics Group PLC (UK)
• bioMérieux (France)
• Romer Labs Division Holding (Austria)
• EUROIMMUN Medizinische Labordiagnostika AG (Germany)
• HollisterStier Allergy (US)
• NEOGEN Corporation (US)
• Eurofins Scientific (Luxembourg)
• Minaris Medical America, Inc. (US)
• Stallergenes Greer (UK)
• HOB Biotech Group Corp., Ltd. (China)
• HYCOR Biomedical (US)
• R-Biopharm AG (Germany)
• AESKU.GROUP GmbH (Germany)
• ACON Laboratories, Inc. (US)
• Lincoln Diagnostics, Inc. (US)
• Astra Biotech GmbH (Germany)
• Erba Group (UK)

SKU-50717